entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 06:02:21 - browse：9

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

WSS

Biden to sign 'historic' executive order on how US military handles sexual assault cases

An outrageous hospital charge: I paid $710 for an hour of babysitting

Ending health disparities requires full federal government, panel says

First Opinion Podcast: How to protect health care in times of war

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Eli Lilly to pay $200M for Beam’s stake in gene

focus

entertainment

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Medical records are filled with copy

Diversifying clinical trials isn't enough to close racial gaps: study

Medicare details structure of new drug price negotiation program

Traditional Chinese medicine benefits explored in new JAMA study

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC recommends rationing of RSV shot due to shortages

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Wikipedia

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: New research from Sanofi, Regeneron, etc.

hotspot

hotspot

hotspot

hotspot